Myopathy is a Risk Factor for Poor Prognosis of Patients with Systemic Sclerosis
A retrospective cohort study
Meiju Zhou, MBBSa,b, Lichun Jiang, MBBSc, Liuyan Nie, MBBSa, Ting Chen, MDd, Ting Zhang, MDa,
Wenjia Sun, MDd, Joshua Sutikno, MBBSa, Yan Du, MDa,∗, Jing Xue, MDb

Abstract
To compare clinical characteristics and identify long-term outcomes of Chinese patients with systemic sclerosis (SSc) with and
without muscle involvement.

We retrospectively investigated the medical records, laboratory results, and computed tomography images of 204 consecutive
SSc patients. Kaplan–Meier analysis was performed to determine survival rates. Patients were allocated into groups with and without
myopathy.

The prevalence of myopathy was 21.6%. The myopathy group was more likely to develop diffuse cutaneous involvement (90.9%
vs 56%, P = 0.006), interstitial lung disease (90% vs 56%, P < 0.001), digestive system involvement (56.7% vs 29.3%, P = 0.001),
pulmonary hypertension (29.5% vs 10.5%, P = 0.004), and pericardial effusion (25% vs. 10%, P = 0.019). Patients with myopathy had
lower single-breath diffusing capacity of the lung for carbon oxide (46.5 ± 11.1 vs 57.1 ± 13.4, P < 0.001). Further, the myopathy group
has similar results in interstitial lung disease associated higher resolution computed tomography score (186.8 ± 64.5 vs 152.3 ± 45.5,
P = 0.037), Valenti score for disease activity (3.4 ± 0.9 vs 2.0 ± 0.9, P < 0.001) and modified Rodnan total skin score (19.4 ± 6.1 vs
15.1 ± 7.7, P = 0.002), compared with non-myopathy group. Kaplan–Meier survival analysis revealed decreased overall survival rate of
the myopathy group (P = 0.028).

SSc Patients with myopathy had more severe clinical manifestations and higher disease activity compared with those without,
which affected survival rates and indicated worse prognosis.

Abbreviations: CK = creatine kinase, dcSSc = diffuse cutaneous SSc, DLCO-SB = single breath diffusing lung capacity for
carbon monoxide, EMG = electromyography, HRCT = high-resolution computed tomography, ILD = interstitial lung disease, lcSSc =
limited cutaneous SSc, LVEF = left ventricular ejection fraction, MRI = magnetic-resonance imaging, mRTSS = modified Rodnan
total skin score, PH = pulmonary hypertension, RP = Raynaud phenomenon, SSc = systemic sclerosis.

Keywords: myopathy, prognosis factors, systemic sclerosis
1. Introduction
Systemic sclerosis (SSc) is a disease of connective tissue with unknown pathogenesis, characterized by fibrosis and microvascular injury to the skin and internal organs. SSc patients are classified into subtypes according to the classification system proposed by LeRoy and Medsger as follows: limited cutaneous SSc (lcSSc), diffuse cutaneous SSc (dcSSc) and sine scleroderma. Most SSc patients have multiple systems involvement, including skin, joints, respiratory system, digestive system, and kidneys, which leads to low quality of life, disability, and possibly death. The presence of antinuclear antibodies occurs with a prevalence ranging from 80% to 98% and Raynaud phenomenon (RP) occurs in approximately 90% to 95% of SSc patients. SSc presents a large mortality than general population. Cumulative survival from diagnosis has been estimated at 74.9% at 5 years and 62.5% at 10 years. Pulmonary involvement represented the main cause of death.

Although myopathy is not a rare symptom associated with SSc, it has not attracted sufficient attention. Approximately 1-third of SSc patients complain of muscle weakness, among which 15% have objective muscle atrophy and 10% have elevated serum creatine kinase (CK). The frequency of myopathy in SSc ranges from approximately 10% to 15% when systematically assessed, and muscle weakness occurs in as many as 90% of these patients.

The clinical manifestation of skeletal muscle involvement, muscle magnetic-resonance imaging (MRI), and electromyography (EMG) of SSc patients are similar to those with polymyositis or dermatomyositis. For example, the Canadian Scleroderma Research Group found that myopathy was a poor prognostic feature of SSc patients, which affects survival rate, particularly in men with early dcSSc with positive anti-topoisomerase1 and anti-RNA polymerase II antibodies, and interstitial lung disease (ILD).

The pathology and mechanisms of SSc-associated myopathy are complex and insufficiently characterized, in contrast to idiopathic inflammatory myopathy. There is not a uniformly accepted case definition for myopathy in SSc or research on SSc-associated myopathy among patients in China. Further, SSc associated myopathy is always neglected in clinical settings. The aim of the study was to delineate the clinical features and survival rates of 204 SSc patients with myopathy who were treated at our institution.

2. Materials and methods

2.1. Patients
We studied SSc patients referred to the Rheumatology Department of our hospital from December 2012 to December 2016. The diagnosis of SSc was made according to the 1980 or 2013 SSc diagnostic criteria proposed by the European League Against Rheumatism/American College of Rheumatology. The Ethics Committee of our hospital approved the study.

2.2. Data collection
Clinical data and laboratory results, which were retrospectively obtained from patients’ medical records, included age, sex, autoantibody titers, SSc subsets, symptoms and signs, organ involvement as well as the modified Rodnan Total Skin Score (mRTSS). Survival status was confirmed by telephonic or hospital records.

2.3. SSc subsets
DcSSc was defined as rapid skin involvement of the trunk, face, proximal and distal extremities frequently associated with antitopoisomerase antibodies. Patients with dcSSc typically exhibited a progressive course of disease with an early onset of RP, often within 1 year after the onset of skin changes.

LcSSc was defined as thickening of the skin of the extremities distal to the knees and elbow joints, facial skin, and the occurrence of RP that typically appeared many years before skin involvement. These patients often produce anti-centromere antibodies.

2.4. Definitions
SSc patients at diagnosis had symptoms of muscle involvement such as fatigue, muscle weakness, muscle pain, and at least 1 of the conditions as follows: serum CK over the normal value (145 U/L); inflammatory changes revealed by muscle biopsy, including necrosis, acute neurogenic atrophy, and fibrosis; EMG showed low voltage, short duration potential during maximal contraction, fibrillation, or sharp waves; muscle MRI showed edema, atrophy, and hyperemia were defined as myopathy. Patients with polymyositis, dermatomyositis, rhabdomyolysis, drug-induced myopathy, necrotizing myopathy, infectious myopathy, toxic myopathy, or metabolic myopathy were excluded, because these diseases may increase serum CK. SSc patients were grouped according to the presence of myopathy.

2.5. Organ involvement
Patients underwent an extensive clinical evaluation that included demographics, disease duration (since the first non-RP symptom), disease subtypes, disease activity, clinical manifestations, and assessment of internal organ involvement.

Pulmonary hypertension (PH) was defined as the estimated systolic pulmonary artery pressure (≥245 mm Hg) according to electrocardiographic measurements of Doppler flow of the tricuspid regurgitant jet. Pericardial effusion was also defined as electrocardiographic measurement.

ILD was diagnosed according to high-resolution computed tomography (HRCT) and pulmonary function tests. The HRCT findings were scored on a scale of 1 to 6, according to the classification method proposed by Kazuya et al., with the variables as follows:

1. normal attenuation,
2. ground glass attenuation without traction bronchiectasis or broncholectasis,
3. consolidation without traction bronchiectasis or broncholectasis,
4. ground glass attenuation with traction bronchiectasis or broncholectasis,
5. consolidation with traction bronchiectasis or broncholectasis,
6. honeycombing. An overall CT score was obtained by adding the 6 averaged scores (3 zones in each lung) assigned by a radiologist.

Gastrointestinal involvement was defined as gastrointestinal motility disturbance, dysphagia, nausea, malabsorption, oesophageal stenosis, gastro-oesophageal reflux, or intestinal pseudo-obstruction.
Kidney involvement was defined as renal insufficiency caused by acute renal crisis (creatinine clearance age-related < 80 mL/min). Disease activity was evaluated according to the Valentini score criteria for SSC. Skin involvement was evaluated using the mRTSS, scale of 0 to 3, which assesses skin hardening and thickness determined by manual palpation of 17 body areas.

2.6. Mortality
The in-hospital mortality was recorded with details of causes and dates of incidence. Details of home deaths were obtained via telephone interviews with each participant’s relatives.

3. Statistical analysis
Descriptive statistics were used to summarize the baseline demographic and clinical characteristics of SSC patients. Statistical analysis was performed using SPSS, version 19.0, statistics for Windows. Survival analysis was performed using GraphPad Prism version 5.1. Continuous variables are presented as the mean ± standard deviation, and discrete variables are reported as the median (min-max). Continuous variables conforming to a Gaussian distribution were evaluated using a t test or the Wilcoxon rank-sum test. Discrete variables were evaluated using the chi-square test. Kaplan–Meier survival analysis was used to determine the survival rates of SSC patients with or without myopathy, and the P value was calculated using the log-rank test. The P values are 2-sided, α = 0.05.

4. Results
4.1. Patients’ characteristics
General characteristics and clinical features in SSC patients with and without myopathy were summarized in Table 1. In the 204 SSC patients, the mean age was 52.8 ± 12.9 years old with 3 (0.2-30) -year disease duration (since the first non-RP). There were 159 women (77.9%) and 45 men (22.1%), with a female/male ratio of 3.5:1. Of the 204 SSC patients, 44 (21.6%) developed myopathy. The 44 patients all had elevated CK, and 12 of them had a higher mRTSS and higher disease activity-related Valetini score (19.4 ± 6.1 vs 15.1 ± 7.7, P = .002 and 3.4 ± 0.9 vs 2.0 ± 0.9, P < .001, respectively). However, there were no significant differences between groups in the frequencies of arthritis, or kidney involvement.

4.2. Comparisons of clinical characteristics
Patients with dcsSc and shorter disease duration were more likely to develop myopathy compared with those with lcSSc. The frequencies of ILD (90.0% vs 55.6%, P < .001), digestive system involvement (56.7% vs 29.3%, P = .001), and digital ulcers (41.2 vs 25.6%, P = .038) were significantly higher in patients with myopathy compared with those without. Further, the myopathy group had a higher mRTSS and higher disease activity-related Valetini score (19.4 ± 6.1 vs 15.1 ± 7.7, P = .002 and 3.4 ± 0.9 vs 2.0 ± 0.9, P < .001, respectively). However, there were no significant differences between groups in the frequencies of arthritis, or kidney involvement.

The variables of cardiopulmonary function associated with visceral organ involvement were assessed and are summarized in Table 2. The myopathy group had a higher incidence of PH, pericardial effusion, higher ILD-HRCT scores, and lower single breath diffusing lung capacity for carbon monoxide. However, there were no differences between left ventricular ejection fraction%, FEV1, or FVC between groups.

### Table 1
Comparison of patients’ clinical characteristics.

| Characteristics | Myopathy (n = 44) | Non-myopathy (n = 160) | P value |
|-----------------|-------------------|------------------------|---------|
| N (%)           | 44 (21.6%)        | 160 (78.4%)            | NA      |
| General features |                   |                        |         |
| Female, n (%)   | 31 (70.5%)        | 128 (80%)              | P = .25 |
| Age (years), mean ± SD | 55.4 ± 11.9 | 53.2 ± 12.8 | P = .35 |
| Disease duration (yr), mean ± SD | 4.7 ± 3.7 | 7.4 ± 5.6 | P = .005 |
| dcsSc, n (%)    | 26 (59.1%)        | 56 (35%)               | P = .006 |
| lcsSc, n (%)    | 18 (40.9%)        | 104 (65%)              | P = .006 |
| Valentini score, mean ± SD | 3.4 ± 0.9 | 2.6 ± 0.9 | P < .001 |
| Pulmonary, n (%) |                   |                        |         |
| Chest tightness | 12 (26.7%)        | 11 (17%)               | P = .01 |
| Short of breath | 16 (36.4%)        | 34 (21.3%)             | P = .06 |
| Cough / expectoration | 3 (6.8%) | 24 (15%) | P = .24 |
| ILD             |                   |                        |         |
| Digestive system, n (%) | 25 (56.7%) | 47 (29.3%) | P = .001 |
| Gastroesophageal reflux | 7 (15.9%) | 31 (19.4%) | P = .76 |
| Dysphagia       | 12 (27.3%)        | 11 (6.7%)              | P = .001 |
| Choking feelings | 6 (13.6%)         | 15 (9.4%)              | P = .34 |
| Kidney, n (%)   |                   |                        |         |
| Elevated creatinine | 6 (13.6%) | 11 (6.8%) | P = .26 |
| Renal crisis    | 2 (4.5%)          | 7 (4.3%)               | P = .71 |
| Oliguria        | 12 (27.3%)        | 26 (16.3%)             | P = .15 |
| Skin and joints, n (%) or mean ± SD |           |                        |         |
| RP              | 30 (68.1%)        | 134 (83.8%)            | P = .036 |
| Arthralgia/ arthritis | 21 (47.7%) | 87 (54.4%) | P = .54 |
| Digital ulcer   | 19 (41.2%)        | 41 (25.6%)             | P = .038 |
| mRTSS           | 19.4 ± 6.1        | 15.1 ± 7.7             | P = .002 |

Disease duration is the number of years since the first non-Raynaud phenomenon. dcSSc = diffuse cutaneous systemic sclerosis subtype, ILD = interstitial lung disease diagnosed using HRCT, lcSSc = limited cutaneous SSC subtype, mRTSS = modified Rodnan total skin score, RP = Raynaud phenomenon, SD = standard deviation.

### Table 2
Assessment of cardiopulmonary function.

| Cardiopulmonary function assessment | Myopathy (n = 44) | Non-myopathy (n = 160) | P value |
|-------------------------------------|-------------------|------------------------|---------|
| Pulmonary hypertension, n (%)       | 13 (29.5%)        | 17 (10.5%)             | P = .004 |
| Hypertension, n (%)                 | 11 (25%)          | 16 (10%)               | P = .019 |
| ILD-HRCT score (Mean ± SD)          | 186.8 ± 64.5      | 152.3 ± 45.5           | P = .037 |
| LVFE% (Mean ± SD)                   | 66.5 ± 9.4        | 66.8 ± 5.8             | P = .91  |
| FEV1                                | 85.9 ± 8.7        | 86.7 ± 11.7            | P = .46  |
| FVC                                 | 79.5 ± 9.7        | 80.3 ± 10.8            | P = .95  |
| DLCO-SB                             | 46.5 ± 11.1       | 57.1 ± 13.4            | P = .001 |
| PASP                                | 44.5 ± 4.1        | 43 ± 11.5              | P = .116 |

DLCO-SB = single-breath carbon monoxide diffusing capacity of the lung, FEV1 = forced expiratory volume in 1 s, FVC = forced vital capacity, ILD-HRCT score = ILD associated higher score of resolution computed tomography (ILD-HRCT) score, LVFE = left ventricular ejection fraction, PASP = Pulmonary Artery Systolic Pressure, PH = pulmonary hypertension.
total. 4 patients died of PH, 5 patients died of malignant tumor, 2 patients died of heart failure, 1 patient died of ILD, and 1 patient died of unknown cause. In myopathy group, 3 died of PH, 1 died of ILD, and 1 died of tumor. In non-myopathy group, 1 died of PH, 4 died of tumor, 2 died of heart failure, and 1 died of unknown cause.

We analyzed the survival rates at baseline. Disease duration was recorded as the number of years since the first non-RP. Kaplan–Meier analysis revealed that compared with patients without myopathy, those with myopathy had lower 3-year (97.7% vs 98.8%), 5-year (95.1% vs 97.8%), and 10-year (81.4% vs 94.1% survival rates; \(P=0.028\)), calculated using the log-rank test (Fig. 1).

### 5. Discussion

The present study was specifically designed to analyze the clinical features and survival rates of SSc patients with and without myopathy. We found that myopathy was not rare in SSc patients (prevalence = 21.6%), using the definition of myopathy described above, which was higher compared with those of other studies (10%–17%).[10] SSc patients with myopathy have more severe skin involvement such as sclerosis and pigmentation changes.[27] Kahan et al reported that 302 Japanese patients with dcSSc experienced myopathy more frequently,[17] and the most common clinical manifestations included muscle atrophy, muscle weakness, and muscle pain, which typically involved the proximal limb muscles such as those of the shoulder muscles, gluteus, and tendon.

### Table 3

| Variable         | Myopathy (n = 44) | Non-myopathy (n = 160) | \(P\) value |
|------------------|-------------------|------------------------|-------------|
| CRP (Mean±SD)    | 8.2±7.3           | 9.7±14.5               | \(P=0.42\)  |
| ESR (Mean±SD)    | 34.8±15.6         | 24.6±20.1              | \(P=0.038\) |
| Cr (Mean±SD)     | 56.5±31.5         | 66.9±62.4              | \(P=0.45\)  |
| BUN (Mean±SD)    | 6.7±7.3           | 8.7±27.3               | \(P=0.89\)  |
| UA (Mean±SD)     | 336.5±153.8       | 303.8±120.9            | \(P=0.082\) |
| LDH (Mean±SD)    | 408.1±168         | 247.1±101.7            | \(P<0.001\) |
| AST (Mean±SD)    | 51.5±60.9         | 24.8±11.5              | \(P<0.001\) |
| ALT (Mean±SD)    | 51.3±45.2         | 24.9±11.5              | \(P<0.001\) |
| CK-MB (Mean±SD)  | 58.1±56.6         | 15.6±6.9               | \(P<0.001\) |
| CK (U/L) (Mean±SD) | 627.4±453.1     | 59.3±30.9              | \(P<0.001\) |

ALT = alanine transaminase, AST = aspartate transaminase, BUN = blood urea nitrogen, CK-MB = creatine kinase-MB, Cr = creatinine, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, LDH = lactic dehydrogenase, SD = standard deviation, UA = uric acid.

**Figure 1.** Survival curves of patients with systemic sclerosis with and without myopathy: Disease duration is the number of years since the first non-Raynaud phenomenon. SSc patients with myopathy had lower survival rates. Kaplan–Meier analysis revealed that the 3-year, 5-year, and 10-year survival rates for SSc patients with myopathy were 97.7%, 95.1%, and 81.4% respectively, compared with those of patients without myopathy, which were 98.8%, 97.8%, and 94.1%, respectively, \(P=0.028\) (the black arrow).
higher disease activity, which affected the survival rate, leading to worse prognosis. Further studies are required to determine the differences between SSC patients with or without myopathy.

**Author contributions**

**Acquisition of data:** Zhou, Nie, Chen, Du, Xue.

**Analysis and interpretation of data:** Zhou, Chen, Du, Xue.

**Manuscript preparation:** Zhou, Du, Sutikno, Zhang, Sun, Xue.

**Statistical analysis:** Zhou, Chen, Du, Xue.

**Study conception & design:** Zhou, Du, Xue.

Du and Xue have full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**References**

[1] Tambly MC, Chanezaud Y, Guillevin L, et al. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003;2:152–7.

[2] van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47.

[3] Domsic RT, Nihyanova SI, Wisniewski SR, et al. Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2014;66:1616–24.

[4] Villalta D, Imbastaro T, Giovanni SD, et al. Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis. Autoimmun Rev 2012;12:114.

[5] Cappelli L, Wigley FM. Management of Raynaud phenomenon and digital ulcers in scleroderma. Rheum Dis Clin North Am 2015;41:149–198.

[6] Rubio-Rivas M, Royo C, Simeon CP, et al. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:208–19.

[7] Clements PJ, Forst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194–203.

[8] Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:734–43.

[9] Jung M, Baron M, Hudson M, et al. Myopathy is a poor prognostic feature in systemic sclerosis. results from the Canadian scleroderma research group (CSRG) cohort. Scand J Rheumatol 2014;43:217–20.

[10] Ranque B, Authier FJ, Bereze A, et al. Systemic sclerosis-associated myopathy. Ann N Y Acad Sci 2007;1108:268–82.

[11] Walker UA, Clements PJ, Allaire Y, et al. Muscle involvement in systemic sclerosis: points to consider in clinical trials. Rheumatology (Oxford) 2017;56:ex38.

[12] Masi AT. ARA Preliminary criteria for the classification of systemic sclerosis (scleroderma): Special article. Arthritis Rheumatol 1980;23:581–90.

[13] Jucun W, Shervin A, Gang G, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol 2013;32:617–21.

[14] Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685–99.

[15] Paik JJ, Wigley FM, Lloyd TE, et al. Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness. Arthritis Care Res (Hoboken) 2015;67:1416–25.

[16] Paik JJ, Wigley FM, Shah AA, et al. Association of fibrosing myopathy in systemic sclerosis and higher mortality. Arthritis Care Res (Hoboken) 2017;69:1764–70.

[17] Mimura Y, Ihn H, Jinnin M, et al. Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol 2005;24:99–102.

[18] Paik JJ, Mammen AL, Wigley FM, et al. Myopathy in scleroderma, its identification, prevalence, and treatment: lessons learned from cohort studies. Curr Opin Rheumatol 2014;26:124–30.

[19] Stone AC, Machan JT, Jeffery M, et al. Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung 2011;189:207–12.
[20] Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013;143:814–24.
[21] Zou J, Guo Q, Chi J, et al. HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients. Clin Rheumatol 2013;34:707–14.
[22] Ichikado K, Suga M, Muranaka H, et al. Prediction of prognosis for acute respiratory distress syndrome with thin-section CT: validation in 44 cases. Radiology 2006;238:321–9.
[23] Gyger G, Baron M. Systemic sclerosis: gastrointestinal disease and its management. Rheum Dis Clin North Am 2015;41:459–73.
[24] Galluccio F, Måller-Ladner U, Furst DE, et al. Points to consider in renal involvement in systemic sclerosis. Rheumatology 2017;56:v49.
[25] Della Rossa A, Valentini G, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001;60:585–91.
[26] Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281–5.
[27] Jinnin M. Mechanisms of skin fibrosis in systemic sclerosis. J Dermatol 2010;37:11–25.
[28] Randone SB, Guiducci S, Cerinc MM. Musculoskeletal involvement in systemic sclerosis. Best Pract Res Clin Rheumatol 2008;22:339–50.
[29] Ranque B, Authier FJ, Le-Guern V, et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009;68:1474–7.
[30] Meune C, Vignaux O, Kahan A, et al. Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010;103:46–52.
[31] Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809–15.
[32] Kahan A, Menkés CJ. Gastrointestinal involvement in systemic sclerosis. Clin Dermatol 1994;12:259.
[33] Domuc RT, Nihyanova Sl, Wisniewski SR, et al. Derivation and external validation of a prediction rule for five-year mortality in patients with early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2016;68:993–1003.